EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut microbiota and antidiabetic drugs: a bidirectional relationship

Spyridoula Kouloumpi, Christina-Maria Trakatelli, Maria Sarigianni, Konstantinos Kitsios, Dimitrios Pilalas, Nikolaos Koletsos, Vasilios Kotsis

Frontiers in Pharmacology · 18.11.2026 · 17

DOI: 10.3389/fphar.2026.2014297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.11.2026. Verfasst von Spyridoula Kouloumpi und 6 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 diabetes remains a global health challenge, with the IDF Diabetes Atlas estimating approximately 537 million adults living with diabetes in 2021 and projections of about 783 million by 2045. While antidiabetic drugs primarily target glucose regulation, accumulating evidence indicates a bidirectional interaction with the gut microbiota that influences both efficacy and adverse effects.

Objective

Review current evidence on interactions between the gut microbiota and the major antidiabetic drug classes, highlighting mechanisms, clinical implications, and opportunities for microbiome-informed precision therapy.

Findings

Metformin is consistently associated with reshaping of gut microbial composition, enriching Akkermansia muciniphila and short-chain fatty acid (SCFA)-producing taxa, alongside improvements in insulin sensitivity and gut barrier function. A randomised study with germ-free mouse faecal transplantation provided direct evidence that the metformin-altered microbiota contributes causally to improved glucose tolerance. Enrichment of Escherichia / Shigella may contribute to gastrointestinal intolerance. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act mainly through incretin pathways but are also associated with increases in Akkermansia and other taxa in animal and human studies, concurrently with weight loss. Sodium-glucose cotransporter 2 inhibitors have been reported to modulate SCFA-producing taxa and gut–tryptophan–GLP-1 signalling in animal models, whereas the dedicated randomised human trial found no change in faecal microbiome composition. Dipeptidyl peptidase-4 inhibitors, thiazolidinediones, and α-glucosidase inhibitors have been reported to exert modest, inconsistent, or population-specific effects on microbial composition, largely in preclinical or small human studies; for α-glucosidase inhibitors, human findings are divergent. In the reverse direction, gut bacteria can biotransform and inactivate acarbose, sequester drugs intracellularly, and degrade luminal GLP-1 through a microbial DPP-4 isozyme not inhibited by sitagliptin, although this evidence is largely in vitro or preclinical.

Conclusion

Antidiabetic drugs and the gut microbiota interact bidirectionally. A microbiota-mediated contribution to therapeutic and adverse outcomes is established for metformin and plausible but unproven for the other classes. Pharmacomicrobiomics offers a framework for personalised diabetes management, including microbiome profiling for prediction of response and microbiota-targeted adjuncts.

Zitieren

APA

Kouloumpi, S., Trakatelli, C., Sarigianni, M., Kitsios, K., Pilalas, D., Koletsos, N., & Kotsis, V. (2026). Gut microbiota and antidiabetic drugs: a bidirectional relationship. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2014297

Vancouver

Kouloumpi S, Trakatelli C, Sarigianni M, Kitsios K, Pilalas D, Koletsos N, et al. Gut microbiota and antidiabetic drugs: a bidirectional relationship. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2014297

BibTeX
@article{Kouloumpi2026,
  author = {Kouloumpi, Spyridoula and Trakatelli, Christina-Maria and Sarigianni, Maria and Kitsios, Konstantinos and Pilalas, Dimitrios and Koletsos, Nikolaos and Kotsis, Vasilios},
  title = {Gut microbiota and antidiabetic drugs: a bidirectional relationship},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.2014297}
}
Kostenlos starten →